Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often
have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an
evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients
with primary hypercholesterolemia where the combination therapy with statins
(HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should
be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total
cholesterol levels compared to monotherapy.